Loading organizations...
Kite Pharma, based in Santa Monica, California, develops novel cancer immunotherapy products, primarily engineered autologous T cell therapies (eACT) to restore the immune system's ability to recognize and eradicate tumors. The company is recognized for pioneering CAR-T therapies, including Yescarta (axicabtagene ciloleucel), which received FDA approval in October 2017 for adult patients with relapsed or refractory large B-cell lymphoma. Kite Pharma went public in 2014 before being acquired by Gilead Sciences for $11.9 billion in August 2017. The acquisition, completed in October 2017, integrated Kite Pharma's pioneering cell therapy platform into Gilead's portfolio. It continues to operate as an independent entity under Gilead, focusing on advancing immuno-oncology research. Kite Pharma was founded in 2009 by Arie Belldegrun. Its business model centers on developed therapies for commercialization, went public in 2014 and was acquired by Gilead Sciences in 2017 for $11.9 billion.
Kite Pharma has raised $20.0M across 1 funding round.
Kite Pharma has raised $20.0M in total across 1 funding round.
Kite Pharma has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series A in May 2013.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2013 | $20M Series A | — | Canaan Partners, Frazier Healthcare Partners, InterWest | Announced |
Kite Pharma has raised $20.0M in total across 1 funding round.
Kite Pharma's investors include Canaan Partners, Frazier Healthcare Partners, InterWest.
# Kite Pharma: A Biopharmaceutical Pioneer, Not a Technology Company
Kite Pharma is not a technology company—it is a biopharmaceutical company dedicated exclusively to developing and commercializing cell therapy treatments for cancer[1][2]. While it employs advanced technology in its operations, its core business model centers on drug development, manufacturing, and patient care rather than technology products or services.
Mission & Focus: Kite is singularly focused on achieving cures with cell therapy, aiming to bring this treatment to as many eligible patients as possible[1]. The company uses genetically modified immune cells—specifically CAR T-cell therapy—that harness a patient's own white blood cells to target and attack cancer cells[1].
What It Builds: Kite develops and manufactures personalized cell therapies, including approved treatments like YESCARTA® (axicabtagene ciloleucel) and TECARTUS® (brexucabtagene autoleucel)[3]. These are individualized, one-time treatments tailored to each patient's immune system[2].
Who It Serves: Patients with blood cancers (hematological malignancies) such as diffuse large B-cell lymphoma, follicular lymphoma, and multiple myeloma, with expanding research into solid tumors and autoimmune diseases[5].
Problem It Solves: For cancer patients who have exhausted conventional treatment options like chemotherapy, Kite's cell therapies offer an alternative approach by reprogramming the immune system to recognize and eliminate cancer cells[1].
Founding & Evolution: Founded in 2009 as a pioneer in cell therapy research, Kite established itself as a leader in immuno-oncology[3]. The company opened its commercial manufacturing site in El Segundo in 2016 and secured a research and development agreement with the National Cancer Institute in 2012[3].
Strategic Acquisition: In October 2017, Kite was acquired by Gilead Sciences, a major biopharma leader[3]. Since becoming an independent operating company within Gilead in 2019, Kite has maintained its singular focus on cell therapy while leveraging Gilead's resources, capabilities, and global infrastructure[3].
Kite operates at the forefront of immuno-oncology and cell therapy innovation, riding the broader trend of personalized medicine and engineered cell therapies as transformational cancer treatments[3]. The company's timing is significant: as conventional chemotherapy reaches its limits for certain cancer types, cell therapy represents a paradigm shift in how oncology is approached.
As part of Gilead—a founding member of the Foundation for the NIH's Partnership for Accelerating Cancer Therapies—Kite influences the broader ecosystem by advancing understanding of cell therapy as a treatment option and expanding access to these specialized therapies globally[3].
Kite's future trajectory centers on expanding cell therapy beyond blood cancers into solid tumors and autoimmune diseases, areas historically challenging for CAR T approaches[5]. The company's recent acquisition of Interius BioTherapeutics (announced August 2025) signals investment in in vivo cell therapy platforms, suggesting a move toward treatments that don't require external manufacturing[6].
The convergence of Kite's specialized manufacturing capabilities, Gilead's global reach, and advancing scientific understanding positions the company to scale cell therapy access—transforming it from a niche treatment for heavily pretreated patients into a broader standard of care for cancer patients worldwide.